Michaela Lehle

Global Development Leader, Hematology
F. Hoffmann-La Roche Ltd.

Presentation(s):

• OC 30.5 - Emicizumab Prophylaxis for the Treatment of People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 6 Study

  Monday, July 11, 2022
  11:45 AM – 12:00 PM

• PB0671 - Analysis of F8 Genotypes and Pharmacodynamic and Safety Biomarkers in People with Moderate or Mild Hemophilia A Receiving Emicizumab in the HAVEN 6 Trial

  Monday, July 11, 2022
  6:30 PM – 7:30 PM